Top 25 Companies in Global Nicotinamide Phosphoribosyl Transferase (NAMPT) Market (2025–2035): Expert View by Spherical Insights
RELEASE DATE: Apr 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The Global Nicotinamide Phosphoribosyl Transferase (NAMPT) is a key enzyme in the nicotinamide adenine dinucleotide (NAD) salvage pathway that regulates cellular energy metabolism and survival. The primary raw materials involved include nicotinamide (vitamin B3), phosphoribosyl pyrophosphate (PRPP), and adenosine triphosphate (ATP), which are essential for enzymatic activity. NAMPT has wide applications in cancer treatment, metabolic disorders, inflammatory diseases, and neurodegenerative conditions, as it plays a crucial role in NAD biosynthesis and cell signaling. Key market trends include growing research on NAMPT inhibitors, increasing demand for targeted therapies, and advancements in precision medicine and biotechnology. Opportunities are emerging in combination therapies and novel drug development targeting metabolic pathways. Government initiatives such as increased funding for oncology research, favorable regulatory policies, orphan drug designations, and fast-track approvals are supporting innovation and accelerating the development and commercialization of NAMPT-based therapeutics globally.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market.
Market Segmentation
Global Nicotinamide Phosphoribosyl Transferase (NAMPT) Market Size, Share, By Product Type (Inhibitors, Activators, and Others), By Application (Cancer Treatment, Metabolic Disorders, Cardiovascular Diseases, and Others), By End-User (Pharmaceutical Companies, Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035
Nicotinamide Phosphoribosyl Transferase (NAMPT) Market Size & Statistics
- The Market Size for Nicotinamide Phosphoribosyl Transferase (NAMPT) was estimated to be worth USD 1.6 Billion in 2025
- The Market is going to Expand at a CAGR of 12.07% between 2025 and 2035.
- The Nicotinamide Phosphoribosyl Transferase (NAMPT) Market Size is anticipated to reach USD 5.0 Billion by 2035.
- North America is expected to generate the highest demand during the forecast period in the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market.
- Asia Pacific is expected to grow the fastest during the forecast period in the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the Nicotinamide Phosphoribosyl Transferase (NAMPT) market. Asia Pacific is expected to grow is driven by increasing cancer prevalence, expanding biotechnology and pharmaceutical industries, rising healthcare investments, growing clinical trial activities, and supportive government initiatives promoting advanced therapeutics and precision medicine development.
North America is expected to generate the highest demand during the forecast period in the Nicotinamide Phosphoribosyl Transferase (NAMPT) market. North America is expected to generate the highest demand in the Nicotinamide Phosphoribosyl Transferase (NAMPT) market driven by advanced healthcare infrastructure, strong presence of leading biotechnology and pharmaceutical companies, high R&D investments, increasing cancer incidence, early adoption of targeted therapies, and supportive regulatory frameworks accelerating NAMPT-based drug development.
Ready to lead the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market
- Rising use of NAMPT inhibitors in oncology
- Growth in precision medicine
- Increasing combination therapies
- Advances in biomarker research
- AI-driven drug discovery
- Focus on NAD⁺ metabolism research
- More biotech–academic collaborations
- Development of selective inhibitors
- Increased government research funding
- Growing orphan drug development initiatives
- Rising use of NAMPT inhibitors in oncology:
NAMPT inhibitors are gaining traction as targeted cancer therapies due to their ability to disrupt tumor metabolism, inhibit NAD⁺ production, and enhance the effectiveness of existing chemotherapy and immunotherapy treatments.
- Growth in precision medicine:
Advancements in precision medicine enable tailored treatments based on genetic and metabolic profiles, increasing the effectiveness of NAMPT-based therapies and improving patient outcomes across oncology and metabolic disease indications.
- Increasing combination therapies:
Combination therapies involving NAMPT inhibitors and other anticancer drugs are expanding, improving therapeutic efficacy, reducing resistance, and offering new treatment strategies for complex and aggressive cancers.
- Advances in biomarker research:
Ongoing research in biomarkers helps identify patients who would benefit most from NAMPT-targeted treatments, enabling early diagnosis, better monitoring, and more personalized therapeutic approaches.
- AI-driven drug discovery:
Artificial intelligence is accelerating NAMPT drug development by optimizing molecule design, predicting drug interactions, and reducing time and cost associated with clinical trials and discovery processes.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Nicotinamide Phosphoribosyl Transferase (NAMPT) market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market.
Top 25 Companies Leading the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Amgen Inc.
- F. Hoffmann-La Roche Ltd
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Novo Nordisk A/S
- Karyopharm Therapeutics Inc.
- Antengene Therapeutics Limited
- Aqualung Therapeutics Corporation
- Onxeo
- OncoTartis
- Nimbus Therapeutics
- AbbVie Inc.
Headquarters: North Chicago, Illinois, USA.
Revenue (2025): approximately USD 56 billion.
AbbVie focuses on oncology, immunology, and neuroscience, with growing interest in metabolic pathways like NAMPT. Its strong pipeline, including targeted cancer therapies and strategic acquisitions (e.g., Allergan), supports innovation. Extensive clinical trials and global commercialization capabilities strengthen its market leadership.
- AstraZeneca plc
Headquarters: Cambridge, UK.
Revenue (2025): approximately USD 47 billion.
AstraZeneca is a leader in oncology and precision medicine, with a robust pipeline targeting tumor metabolism. The company invests heavily in R&D, collaborates with biotech firms, and leverages AI to accelerate drug discovery, including enzyme-targeted therapies like NAMPT inhibitors.
- Bayer AG
Headquarters: Leverkusen, Germany.
Revenue (2025): approximately USD 51 billion.
Bayer operates in pharmaceuticals and life sciences, focusing on oncology and cardiovascular diseases. Its innovation strategy includes targeted therapies and metabolic research. Strong global distribution, digital health initiatives, and partnerships enhance its ability to advance enzyme-based therapeutics.
- Boehringer Ingelheim GmbH
Headquarters: Ingelheim, Germany.
Revenue (2025): approximately USD 28 billion.
Boehringer Ingelheim specializes in oncology, respiratory, and metabolic diseases. The company invests significantly in R&D and biologics, exploring novel enzyme pathways. Strategic collaborations and a patient-centric approach support development of advanced targeted therapies, including NAMPT-related research.
- GlaxoSmithKline plc
Headquarters: London, UK.
Revenue (2025): Approximately USD 38 billion.
GSK focuses on biopharma innovation across oncology, immunology, and infectious diseases. It emphasizes advanced technologies, including genomics and AI, to develop targeted therapies. Strong clinical pipelines, partnerships, and global reach support exploration of metabolic targets such as NAMPT.
Are you ready to discover more about the Nicotinamide Phosphoribosyl Transferase (NAMPT) market?
The report provides an in-depth analysis of the leading companies operating in the Nicotinamide Phosphoribosyl Transferase (NAMPT) market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Nicotinamide Phosphoribosyl Transferase (NAMPT) Market.
Company Profile
- AbbVie Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Others.
Conclusion
The global Nicotinamide Phosphoribosyl Transferase (NAMPT) market is poised for substantial growth, driven by increasing prevalence of cancer and metabolic disorders, alongside rising investments in biotechnology and pharmaceutical research. Advancements in targeted therapies, precision medicine, and NAMPT inhibitor development are accelerating innovation and expanding clinical applications. Favorable government initiatives, including research funding and regulatory support, further enhance market expansion. North America continues to lead in demand due to its advanced healthcare infrastructure and strong R&D capabilities, while Asia Pacific is emerging as the fastest-growing region owing to expanding healthcare investments and clinical activities. Moreover, strategic collaborations, AI-driven drug discovery, and growing focus on metabolic pathways are expected to create new opportunities.
Our Report
https://www.sphericalinsights.com/reports/italy-seed-treatment-market
https://www.sphericalinsights.com/reports/italy-compound-feed-market
https://www.sphericalinsights.com/reports/italy-data-center-market
https://www.sphericalinsights.com/reports/italy-food-colorants-market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?